


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Spector, et al.				
International App. No.:	PCT/US03/10747	Group Art Unit:			
International Filing Date:	April 8, 2003	Examiner:			
For: FAMILY INHIBITOR AN	CANCER TREATMENT METHO ND A RAF AND/OR RAS INHIBIT	D COMPRISING ADMINISTERING AN ERB- OR			
Commissioner for Patent Washington, D.C. 20231					
	INFORMATION DISCLOS	SURE STATEMENT			
Applicants request th Examiner and officially ma	nat the references identified on Form ade of record in accordance with the	PTO-1449 appended hereto be considered by the provisions of 37 CFR 1.97			
[X] A copy of the Into is submitted here attached form PT	erences were submitted in parent apperentional Search Report which issumenth. All of the publications cited in	olication Serial No (37 CFR 1.98(d)) ed on International Application No. PCT/US03/10747 in the International Search Report are listed on the that copies have been supplied to the U.S. Patent			
filing da applicati occurs la	te of the above application or date o	itted herewith is being filed within three months of the fentry into the national stage of an international rst Office action on the merits, whichever event			
of a firs		bmitted herewith is being filed before the mailing Request For Continued Examination under 37			
filing date of an internation event occurre (1) a fil	f the above application or the date on all application or after the mailing ded last, but before the mailing date on all action under § 1.113 or otice of allowance under § 1.311,	ed herewith is being filed after three months of the fentry into the national stage as set forth in § 1.491 of late of the first Office Action on the merits, whichever of either:			
Statement wa		mation contained in this Information Disclosure Foreign patent office in a counterpart foreign he filing of this statement.			
	cts the option to pay the fee set forth atement under § 1.97(c) (\$240.00).	in 37 CFR 1.17(p) for submission of an Information			



C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

John L. Lemanowicz Attorney for Appliant

Registration No. 37,380

Date: 10/1/04
GlaxoSmithKline

Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8247 Facsimile: (919) 483-7988

DISERSE POT/PTO 0 7 OCP-2884

FORM PT	0-144	9			ATTORNEY DOC	KEŢ	1115 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
INFORMATION DISCLOSURE STATEMENT				NO.).					
					PU4725USW PCT/US03/10747						
					APPLICANT						
					Spector et al. INTERNATIONAL	,	CDOIM				
					FILING DATE	L .	GROUP				
					4/8/03						
U.S. PATENT DOCUMENTS											
			0.0.7.				T	Filing Date			
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	If Appropriate			
	1	6,727,256	4/27/04	Carter et al.							
	2	6,713,485	3/30/04	Carter et al.							
	3	6,169,091	1/2/01	Cockerill et al.							
	4	6,174,889	1/16/01	Cockerill et al.							
	5	6,723,726	4/20/04	Cockerill et al.							
	6	6,207,669	3/27/01	Cockerill et al.		···					
	7	6,391,874	5/21/02	Cockerill et al.							
				L			1				
				ntinue on p							
				PATENT	DOCUMENTS			Translation			
		Document Number	Publication Date	Country		Class	Subclass	Yes No			
	8	02/056912	7/25/02	PCT	Country	Class	Bubciass				
	-	02/030912	1123102	101							
	<u> </u>			<u> </u>							
	·		Co	ntinue on p	page	•					
	OT	HER DOCUME	NTS (Includin	g Author,	Title, Journal-Date,	Page Nu	mber, Etc.)				
	9	Martinez-Lacaci, E.A., "RAS transformation causes sustained activation of epidermal growth									
			factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial								
	<u> </u>	cells," International Journal of Cancer, Vol. 88, No. 1, 2000, pp. 44-52.									
	10	He, E.A., "Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation," Cancer Journal, Vol. 7, No. 3, 2001, pp. 191-202.									
	<u> </u>										
	ļ						·				
	 						-				
· · · · · · · · · · · · · · · · · · ·			-								
Continue or rece											
EXAMINER DATE CONSIDERED											
					tation is in conformar iclude copy of this for						